English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chronic obstructive pulmonary disease is prevalent condition commonly associated with cardiovascular diseases. When both are combined the prognosis of the patient worsens. One cornerstone therapy for most cardiac diseases is beta-blockade, however concerns about its potential harmful effects on airways function often restrains their use in patients with COPD and coexistent cardiac diseases. While selective beta1 adrenergic blockers seem to have a better safety profile, other non-selective beta-blockers can be securely utilized in stable COPD patients with no or little reactivity when they are indispensable and used with caution.

Beta-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses